S-1/A: Salarius Pharma Merges with Decoy Therapeutics, Raises $6.4M

Salarius Pharmaceuticals is merging with Decoy Therapeutics, shifting its focus to peptide conjugate drug discovery and raising $6.4M in a public offering.

Summary

• Salarius Pharmaceuticals (SLRX) is merging with Decoy Therapeutics Inc. (Decoy) in a two-step transaction, with the combined entity to be renamed Decoy Therapeutics, Inc.
• The merger is conditioned upon Salarius raising at least $6.0 million in a 'Qualified Financing' and maintaining its Nasdaq listing.
• Salarius is offering 1,518,027 shares of common stock, Series A Warrants, and Series B Warrants at an assumed combined public offering price of $5.27 per share, aiming to raise an estimated $6.4 million in net proceeds (or $7.5 million if the underwriters' over-allotment option is fully exercised).
• Pre-funded warrants are also offered as an alternative for purchasers whose beneficial ownership would otherwise exceed 4.99% (or 9.99% at election).
• Post-merger, Salarius legacy stockholders are expected to retain approximately 18.3% and Decoy stockholders 81.7% of the combined company, before accounting for the dilutive effects of this offering.
• Decoy's business centers on its proprietary IMP³ACT™ platform for peptide conjugate drug discovery, initially targeting infectious diseases and oncology, leveraging machine learning and AI.
• Salarius' SP-3164 compound will be integrated into Decoy's platform to create peptide-based proteolysis targeting chimeras (P-PROTACs).
• Salarius closed its Phase 1/2 clinical trial for SP-2577 in Ewing sarcoma to conserve cash but continues to support an MDACC-sponsored trial for SP-2577 in myelodysplastic syndromes and chronic myelomonocytic leukemia, which recently had a partial clinical hold lifted.
• Decoy's antiviral drug candidates showed promising in silico activity against measles and Nipah viruses, with in vitro activity demonstrated against hPIV3, RSV A, and RSV B (EC50 < 1 uM).
• The Series A and B Preferred Stock issued to Decoy security holders will have anti-dilution price protection with an initial issuance price of $10.50 and a floor price of $3.75, potentially increasing the number of common shares upon conversion.
• Approximately $645,000 of the offering proceeds will be used to pay off certain of Decoy's outstanding promissory notes.
• Salarius estimates $4.1 million in cash and cash equivalents as of September 19, 2025.
• Salarius received Nasdaq delisting notices for not meeting the $1.00 minimum bid price (April 23, 2025) and the $2.5 million stockholders' equity requirement (March 26, 2025).
• Nasdaq granted extensions, with the minimum bid price requirement regained by September 4, 2025, and the Equity Standard deadline extended to October 20, 2025; the merger is expected to help regain compliance with the Equity Standard.

Sentiment

Score: 3

Explanation: The filing details a critical merger and financing necessary for Salarius' survival and continued Nasdaq listing, addressing severe financial distress and delisting threats. While the merger offers a strategic pivot and new pipeline, the underlying financial weakness, significant dilution, and ongoing regulatory hurdles (especially the Equity Standard deadline) present substantial risks and indicate a challenging situation.

Positives

• Strategic merger with Decoy Therapeutics, pivoting Salarius into the novel and growing peptide conjugate drug discovery space with Decoy's IMP³ACT™ platform.
• Integration of Salarius' SP-3164 compound into Decoy's P-PROTAC platform, expanding therapeutic opportunities in oncology.
• Decoy's platform leverages machine learning and AI for rapid engineering and optimization of peptide conjugates, potentially accelerating drug development.
• Promising preclinical in silico activity of Decoy's antiviral candidates against measles and Nipah viruses, and demonstrated in vitro activity against hPIV3, RSV A, and RSV B (EC50 < 1 uM).
• The partial clinical hold on the MDACC-sponsored SP-2577 trial in myelodysplastic syndromes and chronic myelomonocytic leukemia has been lifted, allowing patient enrollment to resume.
• Salarius successfully regained compliance with Nasdaq's minimum bid price requirement by September 4, 2025.
• The current financing is expected to provide $6.4 million in net proceeds, which is crucial for the combined company's operations and research and development programs.
• The merger is anticipated to enable Salarius to regain compliance with Nasdaq's Equity Standard requirement.

Negatives

• Salarius closed its Phase 1/2 clinical trial for SP-2577 in Ewing sarcoma due to a lack of funding, indicating significant financial constraints prior to the merger.
• Salarius' common stock price experienced substantial deterioration between January 2025 and June 2025, materially affecting the relative valuations underlying the merger exchange ratio.
• The offering and the conversion of preferred stock will result in significant dilution for existing Salarius stockholders and new investors.
• Decoy's financial condition raises substantial doubt about its ability to continue as a going concern, with a significant accumulated deficit of $(27,826,847) as of June 30, 2025.
• Decoy has never generated revenue from product sales, and all its product candidates are currently in the preclinical stage, implying a long and uncertain path to commercialization and profitability.
• The combined company will likely need to raise additional funds sooner than currently planned if cash holdings are lower than anticipated or R&D costs exceed estimates.
• The anti-dilution price protection for Series A and B Preferred Stock, with an initial issuance price of $10.50 and a floor of $3.75, means that if the offering price or future financing prices are lower, more common shares will be issued to preferred stockholders, causing further dilution.
• Nasdaq delisting risk remains if the Equity Standard is not met by the extended deadline of October 20, 2025, or if the post-merger entity fails to meet initial listing standards.
• There is no established public trading market for the pre-funded or common warrants, which will limit their liquidity.

Risks

• The merger may be completed even if certain events occur prior to the Merger Closing that materially and adversely affect Salarius or Decoy.
• Nasdaq may delist the combined company's securities from trading if it fails to satisfy initial listing criteria or regain compliance with the Equity Standard by October 20, 2025.
• Stockholders of the combined company may not realize a benefit from the merger commensurate with the substantial ownership dilution experienced from the merger and the Qualified Financing.
• The historical unaudited pro forma condensed combined financial information may not be representative of the combined company's results after the merger.
• Restrictions in the Merger Agreement may prevent Salarius and Decoy from entering into a business combination with another party at a favorable price.
• Certain provisions of the Merger Agreement, including a potential $300,000 termination fee, may discourage third parties from submitting alternative takeover proposals.
• Salarius is required to recommend stockholder approval for the conversion of Preferred Stock, but cannot guarantee it will be obtained, which could materially harm operations.
• The lack of a public market for Decoy's capital stock makes its valuation difficult, potentially leading to Decoy stockholders receiving shares with a value greater than fair market value.
• The combined company may become involved in securities class action litigation, diverting management's attention and incurring costs.
• The Merger Agreement may be terminated, and failure to complete the merger would negatively impact Salarius' stock price and financial results.
• The market price of Salarius common stock may decline following the merger due to negative investor reactions or failure to achieve anticipated benefits.
• Salarius and Decoy security holders will have a reduced ownership and voting interest in the combined company.
• The combined company will need to raise additional capital, which may cause further dilution or restrict operations.
• The price protection provisions in the Series A and Series B Certificate of Designations may cause additional dilution to Salarius stockholders if future financings are priced below the Initial Issuance Price of $10.50.
• Salarius has broad discretion in how it uses the proceeds of this offering, which may not be effective.
• Salarius does not intend to pay dividends, so any return to investors is expected solely from stock price increases.
• The trading price of Salarius common stock could be highly volatile, leading to substantial losses for purchasers.
• There is no public market for the pre-funded warrants or common warrants, limiting their liquidity.
• Holders of pre-funded and common warrants will have no rights as common stockholders until exercise.
• Salarius may not receive additional funds upon cashless exercise of pre-funded warrants.
• Significant holders may be limited in exercising warrants due to beneficial ownership limitations.
• If the merger is not completed, Salarius may not be able to source adequate liquidity and could face dissolution and liquidation.
• The pendency of the merger could adversely affect Salarius' stock price and business.
• Decoy's financial condition raises substantial doubt regarding its ability to continue as a going concern.
• Decoy has never generated revenue from product sales, and all its product candidates are in the preclinical stage, making future success uncertain.
• Early-stage drug development requires major capital investment, and Decoy will need to raise additional capital or form strategic partnerships.
• Unsuccessful or terminated strategic alliances could hinder Decoy's development and commercialization efforts.
• Reliance on third parties for clinical trials and manufacturing entails risks of non-performance, delays, and regulatory non-compliance.
• Decoy's novel drug discovery approach using AI/ML is unproven and may not lead to marketable products.
• Failure to identify or discover additional potential product candidates could result in loss of investment.
• Decoy faces significant competition from major pharmaceutical and biotechnology companies.
• Cybersecurity threats and other security disruptions could negatively impact Decoy's business.
• Failure of Decoy's information technology infrastructure could adversely affect its business.
• Commercial success depends on acceptance by the medical community and payors, which is uncertain.
• Changes in the U.S. presidency and regulatory environment could adversely affect Decoy's business.
• Inability to establish sales and marketing capabilities or enter into third-party agreements could prevent revenue generation.
• International operations carry additional risks if products are commercialized abroad.
• Loss of key management or scientific personnel could materially suffer the business.
• Compliance with healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws is critical.
• Potential product liability claims could incur substantial liability and costs.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or penalties.
• Business interruptions from pandemics, natural disasters, and adverse weather events could cause R&D delays.

Future Outlook

The combined company plans to advance the clinical development of its research and development programs, initially focusing on infectious diseases and oncology using Decoy's IMP³ACT™ platform. It intends to integrate Salarius' SP-3164 into a P-PROTAC platform. The company expects to satisfy Nasdaq initial listing criteria and obtain stockholder approval for preferred stock conversion following the financing and merger closing. It aims to fund operations through year-end 2026 and into Q1 2027 with current cash, Gates Foundation funds, and offering proceeds.

Management Comments

• Salarius and Decoy believe the synergies between Decoy and Salarius are evident in their combined approach to drug development.
• Decoy's expertise in peptide conjugates complements Salarius' small molecule assets. This combination could enable the combined company to address a wider range of diseases and potentially undruggable targets.
• Decoy believes the IMP³ACT platform has the potential to change the economics of antiviral drug development by addressing multiple high health burden viruses such as respiratory syncytial virus (RSV) and human parainfluenza virus 3 (hPIV3) and preparing the world for emerging future threats with a single drug.
• Decoy therefore believes that there is a reasonable probability that the rationally designed fusion inhibitor will show similar activity against Measles and Nipah in in vitro pseudotype assays.
• Salarius and its management team negotiated the most favorable implied value and equity split for its stockholders that Decoy was willing to agree to.
• The Salarius board of directors believed that the Merger is more favorable to its stockholders than the potential value that might have resulted from other strategic options available to Salarius, which would likely be a liquidation of Salarius and the distribution of any available cash if the Merger is not consummated.

Industry Context

The merger positions the combined entity in the growing market for peptide conjugate technology, a major therapeutic drug modality exemplified by successful diabetes and weight loss treatments like Ozempic, Wegovy, Mounjaro, and ZepBound. Decoy's use of AI/ML in drug discovery aligns with modern biopharma trends. The focus on high-unmet-need therapeutic areas such as infectious diseases (e.g., RSV, hPIV3, measles, Nipah, pan-Coronavirus) and oncology (colorectal cancer, P-PROTACs) is strategically relevant. The integration of small molecules with peptide platforms represents an evolving strategy to expand targetable proteins and potentially improve safety profiles.

Comparison to Industry Standards

• Decoy's IMP³ACT™ platform is described as a 'paradigm shift' in peptide conjugate drug discovery and manufacturing, leveraging machine learning and artificial intelligence tools, suggesting an innovative approach compared to traditional methods.
• Peptide conjugates are highlighted as an 'emerging major therapeutic drug modality,' with successful diabetes and weight loss treatments (Ozempic, Wegovy, Mounjaro, ZepBound) cited as examples of industry success in this class.
• Peptide drug conjugates are compared to antibody-drug conjugates (ADCs) for targeted delivery, with the potential for increased tissue penetration and lower cost, indicating a competitive advantage in targeted therapy.
• Decoy's antiviral drug candidates demonstrated in vitro activity (EC50 < 1 uM) against hPIV3, RSV A, and RSV B, a common metric for drug potency, suggesting competitive efficacy in early-stage development.
• The filing notes that approximately 70% of drugs proceed past Phase 1 studies, 33% past Phase 2, and just 25%-30% proceed past Phase 3 to Phase 4, underscoring the high failure rate and significant challenges inherent in drug development across the industry.

Management Changes

Corporate Governance

Legal Proceedings

• No action, suit, inquiry, notice of violation, proceeding or investigation is pending or, to the knowledge of the Company, threatened against or affecting Salarius, any Subsidiary or their properties which (i) adversely affects or challenges the legality, validity or enforceability of any Transaction Documents or Securities or (ii) could result in a Material Adverse Effect.
• Neither Salarius nor any Subsidiary, nor any director or officer, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.
• There has not been, and to the knowledge of Salarius, there is not pending or contemplated, any investigation by the Commission involving Salarius or any current or former director or officer.
• The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by Salarius or any Subsidiary.

Related Party Transactions

• Approximately $140,000 of Decoy's non-interest bearing notes held by its founders and officers (Rick Pierce, Barbara Hibner, Peter Marschel) will remain outstanding and will not be repaid from the offering proceeds, with maturity dates extending 12 months beyond the Merger Closing.
• Certain Salarius officers and directors entered into stockholder support agreements to vote in favor of the Salarius Stockholder Matters.
• Decoy officers and directors, in their capacities as stockholders of Decoy, entered into stockholder support agreements to vote in favor of the proposed Merger.
• Concurrently with the execution of the Merger Agreement, certain Decoy officers and directors, and certain Salarius directors and officers entered into 180-day lock-up agreements on the sale or transfer of shares.

Stakeholder Impact

• Shareholders (existing Salarius): Will experience substantial dilution from the public offering and the conversion of Preferred Stock, but gain potential long-term value from the combined company's new strategic direction and pipeline. Face ongoing risk of delisting if Nasdaq's Equity Standard is not met.
• Shareholders (Decoy): Will own a substantial majority (81.7%) of the combined company, gaining access to a Nasdaq-listed entity and potential liquidity in public markets. Their Preferred Stock is subject to anti-dilution protection.
• New Investors in Offering: Will experience immediate and substantial dilution, investing in a company with a new strategic focus and preclinical pipeline, subject to significant development and regulatory risks.
• Employees: Decoy's senior management team will assume key executive roles in the combined company, while Salarius' remaining employees are crucial for the merger's consummation.
• Creditors (Decoy): Certain outstanding promissory notes totaling approximately $645,000 will be paid off from the offering proceeds, while approximately $140,000 in notes held by Decoy's founders/officers will remain outstanding.
• Regulatory Bodies (Nasdaq): The company is actively engaged with Nasdaq to regain and maintain compliance with listing rules, with the merger and financing intended to address the Equity Standard deficiency.

Next Steps

• Complete the public offering and the merger concurrently.
• File an initial listing application with Nasdaq for the post-transaction entity.
• Call a special stockholder meeting to approve the conversion of Preferred Stock into common stock, a new equity incentive plan, and potentially another reverse stock split.
• Register the issuance of common stock underlying the Preferred Stock within 60 days of the Merger Closing.
• Advance clinical development of the combined company's research and development programs, including Decoy's pan-Coronavirus fusion inhibitor program (IND-enabling activities), broad-acting respiratory antiviral fusion inhibitor program (lead molecule design), and colorectal cancer GPCR-based peptide conjugate program.
• Conduct chemistry proof of concept work for Salarius' proprietary compound SP-3164.
• Continue supporting MDACC's ongoing investigator-initiated clinical trial evaluating seclidemstat (SP-2577).
• Regain compliance with Nasdaq's Equity Standard by October 20, 2025.
• Change the combined company's name to Decoy Therapeutics, Inc. and obtain a new Nasdaq ticker symbol.

Key Dates

Recommendation

The merger with Decoy Therapeutics offers Salarius a critical lifeline and a strategic pivot into the promising peptide conjugate drug discovery space, leveraging AI/ML. This move addresses Salarius' severe financial distress and Nasdaq delisting threats. However, the significant dilution for existing shareholders, Decoy's preclinical stage and lack of revenue, and the ongoing uncertainty surrounding Nasdaq's Equity Standard compliance and the full conversion of preferred stock introduce substantial risks. While the new pipeline has potential, it is early-stage, and the path to profitability is long and uncertain. A 'hold' recommendation is appropriate as the company navigates this complex transition, with investors needing to monitor execution of the merger, successful capital deployment, and progress in the preclinical and early clinical pipeline. The immediate dilution and financial fragility warrant caution, but the strategic shift and potential of the new platform prevent a 'sell' recommendation.

Keywords

Biopharmaceutical, Merger, Decoy Therapeutics, Salarius Pharmaceuticals, Nasdaq, Public Offering, Warrants, Peptide Conjugates, P-PROTACs, SP-3164, SP-2577, Oncology, Infectious Diseases, Clinical Trials, Preclinical, AI, Machine Learning, Capital Raise, Delisting, Equity Standard, Anti-dilution, Corporate Governance, Risk Management